| 马玲彦,宋冬青,葛胜华.维生素 A与蛋白琥珀酸铁联合治疗学龄前儿童缺铁性贫血伴维生素 A缺乏的效果及对复发率的影响[J].安徽医药,2026,30(6):1231-1235. |
| 维生素 A与蛋白琥珀酸铁联合治疗学龄前儿童缺铁性贫血伴维生素 A缺乏的效果及对复发率的影响 |
| Efficacy of vitamin A combined with iron proteinsuccinate in the treatment of preschool children with iron deficiency anemia and vitamin A deficiency and its effect on recurrence rate |
| |
| DOI：10.3969/j.issn.1009-6469.2026.06.034 |
| 中文关键词: 贫血，缺铁性 维生素 A缺乏 学龄前儿童 蛋白琥珀酸铁 疗效 铁代谢 复发 |
| 英文关键词: Anemia, iron-deficiency Vitamin A deficiency Preschool children Iron albuminosuccinate Curative effect Iron metabolism Recrudescence |
| 基金项目:河北省医学科学研究课题计划( 20231612) |
|
| 摘要点击次数: 48 |
| 全文下载次数: 13 |
| 中文摘要: |
| 目的探讨维生素 A联合蛋白琥珀酸铁治疗学龄前儿童缺铁性贫血( IDA)伴维生素 A缺乏的效果及其对复发率的影响。方法前瞻性选取 2021年 1月至 2023年 7月石家庄市人民医院收治的学龄前 IDA伴维生素 A缺乏病儿 210例，采用随机数字表法分为对照组、研究组，各 105例。对照组按照 1.5 mL·kg.1·d.1口服蛋白琥珀酸铁， 2次/天。研究组在对照组基础上口服维生素 A软胶囊，每次 2.5万 IU，1次/天，连续服用 7d后停药 3d，以 10 d为 1个治疗周期。两组均连续治疗 30 d。比较两组治疗效果、临床症状体征改善时间及治疗前后实验室指标水平。比较两组不良反应及治疗后 6个月复发率。结果研究组总有效率为 97.14%(102/105)，高于对照组的 81.90%(86/105)(P<0.05)；研究组皮肤和黏膜苍白、头晕、精神不振、食欲不振改善时间短于对照组( P<0.05)；研究组治疗后血红蛋白( Hb)、红细胞压积( HCT)、平均红细胞体积( MCV)、平均红细胞血红蛋白含量( MCH)、平均红细胞血红蛋白浓度( MCHC)、血清铁、铁蛋白水平分别为( 132.16±8.10)g/L、(38.82±3.44)%、(85.79±9.03)fL、(28.42±4.16)pg、(329.10±33.24)g/L、(18.62±3.04)μmol/L、(35.72±5.18)μg/L，高于对照组的( 118.34±7.39)g/L、(36.13±2.81)%、(76.21±7.51)fL、(25.11±3.62)pg、(306.27±26.48)g/L、(16.57±2.38)μmol/L、(30.31±4.36)μg/L，转铁蛋白( TRF)水平为( 2.01±0.20)g/L，低于对照组的( 2.25±0.27)g/L(P<0.05)；研究组治疗后血清维生素 A水平为( 1.15±0.35)μmol/L，高于对照组的( 0.94±0.31)μmol/L(P<0.05)而对照组治疗前后血清维生素 A水平差异无统计学意义( P>0.05)；两组不良反应对比差异无统计学意义( P>0.05)；研究组后 6个月复发率 4.85%(5/103)低于对照组 17.65%(18/102)(P<0.05)。结论维生素 A联合蛋白琥珀酸铁治疗学龄前 IDA伴维生素 A缺乏病儿的疗效确切，可改善临床症状、贫血状态，促进铁代谢恢复，降低复发率，且未增加不治疗，良反应发生率。 |
| 英文摘要: |
| Objective To investigate the efficacy of vitamin A combined with iron proteinsuccinate in the treatment of preschool chil.dren with iron deficiency anemia (IDA) and vitamin A deficiency and its effect on recurrence rate.Methods A total of 210 preschoolchildren with IDA and vitamin A deficiency admitted to Shijiazhuang People's Hospital from January 2021 to July 2023 were prospec.tively enrolled. They were randomly divided into a control group and a study group using a random number table method, with 105 cas.es in each group. Patients in the control group were given oral iron protein succinate at 1.5 mL·kg.1·d.1, twice daily. Patients in thestudy group received oral vitamin A soft capsules 25 000 IU once daily in addition to the treatment of the control group, administeredfor 7 consecutive days followed by a 3-day withdrawal, with 10 days constituting one treatment cycle. Both groups were treated for 30days. The therapeutic efficacy, times to improvement of clinical symptoms and signs, and laboratory parameters before and after treat.ment were compared between the two groups. Adverse reactions and the recurrence rate at 6 months after treatment were also compared.Results The total effective rate in the study group was 97.14% (102/105), which was significantly higher than 81.90% (86/105) in thecontrol group (P<0.05). The time of improvement pale skin and mucous membranes, dizziness, lassitude, and loss of appetite were sig.nificantly shorter in the study group than in the control group (P<0.05). After treatment, the hemoglobin (Hb), hematocrit (HCT), meancorpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), serum ironand ferritin levels in the study group were (132.16±8.10) g/L, (38.82±3.44)%, (85.79±9.03) fL, (28.42±4.16) pg, (329.10±33.24) g/L,(18.62±3.04) μmol/L, and (35.72±5.18) μg/L, respectively, which were significantly higher than those in the control group [(118.34±7.39) g/L, (36.13±2.81)% , (76.21±7.51) fL, (25.11±3.62) pg, (306.27±26.48) g/L, (16.57±2.38) μmol/L, and (30.31±4.36) μg/L]; thetransferrin (TRF) level in the study group was (2.01±0.20) g/L, which was significantly lower than that in the control group [(2.25±0.27)g/L (P<0.05)]. After treatment, the serum vitamin A level in the study group was (1.15±0.35) μmol/L, which was significantly higherthan that in the control group (0.94±0.31) μmol/L (P<0.05)], whereas there was no significant difference in the serum vitamin A level in the control group before and after treatment (P>0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). The recurrence rate in the study group at 6 months after treatment was 4.85% (5/103), which was significantly lower than thatin the control group at 17.65% (18/102) (P<0.05).Conclusions Vitamin A combined with iron proteinsuccinate is effectively in treat.ing preschool children with IDA and vitamin A deficiency. It can improve clinical symptoms and anemia, promote iron metabolism re.covery, reduce the recurrence rate, and does not increase the incidence of adverse reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
